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Abstract Antisense oligonucleotides efficiently inhibit gene expression in vitro; however, the 
successful therapeutic application of this technology in vivo will require the development of 
improved delivery systems. In this report we describe a technique that efficiently delivers antisense 
oligonucleotides into cells using molecular conjugates. This technique, which was initially devel- 
oped for the delivery of eukaryotic genes, is based on the construction of DNA-protein complexes 
that are recognized by the liver-specific asialoglycoprotein receptor. Binding of poly(L-Iysine)- 
asialoorosomucoid (AsOR) protein conjugates with phosphorothioate antisense oligonucleotides 
to chloramphenicot acetyltransferase (CAT) led to the formation of 50- to t50-nm toroids. 
Exposure of the antisense molecular complexes" (3 IxM oligonucleotide) to NIH 3T3 cells 
genetically modified to express both the AsOR receptor and CAT, inhibited CAT expression by 
54%, which was completely blocked by excess AsOR. Equivalent inhibition of  CA T activity with 
purified oligonucteotide alone was obsen, ed at a 30 ~ concentration. Furthermore, examination 
of  the cells using indirect immunofluorescence for the presence of  CAT protein showed 28% of 
cells exposed to the molecular conjugates lacked any detectable CAT enzyme. Cells exposed to 
oligonucleotide alone showed a highly variable staining pattern, and only a few of the cells were 
completely void of  CAT protein. Together these dam demonstrate that molecular conjugates 
provide a highly specific and efficient system for the delivery of antisense oligonucleotides. 
INTRODUCTION 
The existence of naturally occurring 
antisense RNA molecuIes has been de- 
scribed in prokaryotes and more recently 
eukaryotes (1, 2). It is believed that these 
RNAs directly inhibit gene expression by 
hybridizing to the complementary sense 
sequences. Since their discovery, there has 
been intense interest in developing antisense 
nucleic acid technology for use as therapeu- 
tic agents against viruses and oncogenes. 
The ability to synthetically produce 
antisense sequences in the form of oligonucle- 
otides has greatly facilitated the develop- 
ment of antisense reagents because they can 
be produced in large quantities and can be 
designed to exacting specifications. Experi- 
ments performed with standard phosphodies- 
ter-linked antisense oligonucleotides have 
met with varying degrees of success (3-6). 
The major limitation has been the develop- 
ment of methods for efficient delivery of 
oligonucleotides into appropriate compart- 
ments of the cell. The data from such 
experiments indicate that short oligonucieo- 
tides are transported into the cell by an 
active transport mechanism and are capable 
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of inhibiting gene expression (7, 8). The in 
vivo applications of phosphodiester based 
oligonucleotides have been disappointing 
due to their sensitivity to nucleases, as well as 
very low efficiency of transport across the cell 
membrane. 
In an attempt to alleviate the transport 
and nuclease sensitivity problems, oligonucle- 
otides with nonionic internucleotide linkages 
have been developed (9). Several types of 
modified phosphate linkages have been gen- 
erated, including phosphothioesters, phos- 
phoaramidates, and methyl phosphonates 
(10-13). A significant advantage of the 
modified oligonucleotides is that they have 
an extended half-life within the cell because 
the modified internucleotide linkages make 
them highly resistant to nucleases (14, 15). 
The chemically modified oligonucleotides 
are also nonionic molecules that may have 
enhanced permeability to the cell membrane 
(16) and may have enhanced binding activi- 
ties for target sequences under physiologic 
conditions (17). Extensive investigation into 
the use of these modified oligonucleotides as 
potential agents against viral infections both 
in vitro and in vivo has revealed them to be 
highly effective at specifically blocking viral 
replication without being toxic to cells 
(18-20). Although the modified oligonucleo- 
tides have shown great potential for use as 
therapeutic molecules, they have not become 
clinically practical because of the large 
quantities of oligonucleotide necessary to 
achieve a significant reduction in gene 
expression and lack of specificity in terms of 
delivery in vivo. Currently, there are no 
methods to efficiently and specifically deliver 
large quantities of oligonucleotide to a high 
proportion of eukaryotic cells in vitro or in 
vivo. 
Molecular conjugates, a soluble DNA 
carrier system, were initially developed as a 
method for targeting the transfection of 
genes to specific cells (21, 22). The conju- 
gates utilize receptor-mediated endocytotic 
mechanisms for delivering genes into cells. 
The principle behind ptasmid-based molecu- 
lar conjugates is that the negatively charged 
DNA will electrostatically interact with posi- 
tively charged polylysine to form compact 
structures called toroids. By covatentIy link- 
ing a specific receptor ligand, such as 
asialoorosomucoid or transferrin, to the 
polylysine to form DNA-protein complexes, 
it has been possible to target cell-specific 
surface receptors and transfect plasmid 
DNA into cells (23). Recently, functional 
conjugates were generated to cell surface 
receptors for asialoorosomucoid (AsOR) 
and transferrin (24, 25). Using the AsOR 
molecular conjugates, hepatocyte-targeted 
gene delivery has been studied in vivo using 
several different animal models, including 
the Watanabe heritable hyperIipidemic rab- 
bit (26). 
In the present study, AsOR molecular 
conjugates were investigated as a potential 
delivery system for antisense oligonucleo- 
tides. The study consisted of forming DNA- 
protein complexes between phosphorothio- 
ate antisense oligonucleotides directed 
toward chloramphenicol acetyltransferase 
(CAT) and the AsOR-polylysine conjugates. 
Electron microscopy revealed that the molec- 
ular conjugates formed classic toroidal struc- 
tures. The antisense molecular conjugates 
were then analyzed for their ability to inhibit 
CAT activity in stably transfected cells using 
indirect immunofluorescence and enzymatic 
assays. The data presented here demonstrate 
that formation of molecular conjugates with 
an antisense oligonucleotide provides a highly 
efficient delivery system for large quantities 
of oligonucleotide to a high proportion of 
target cells. The use of molecular conjugates 
for the delivery of oligonucleotides may thus 
prove to be an effective approach for the 
development of antisense otigonucleotides as 
potential therapeutic agents. 
MATERIALS AND METHODS 
Preparation of Targetable Conjugate. Oro- 
somucoid (Sigma) was enzymatically treated 
for 30 h with neuraminidase derived from 
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Vibrio cholerae (Boehringer Mannheim Bio- 
chemical) to cleave terminal sialic acid 
groups, thus generating AsOR, which was 
cross-linked at pH 8.0 to poly-L-lysine 
(MW,,~ = 21.7 kDa; Sigma) at a molar ratio 
of 1.3:1 for 15 h in the presence of a molar 
excess of 1-ethyl-3-(3-dimethytaminopropyl) 
carbodiimide (EDC; Pierce Chemical Co.). 
AsOR-poly(L-lysine) conjugate was purified 
by ion-exchange chromatography (CM-Bio 
Gel A; Bio-Rad). Fractions containing conju- 
gate were identified by their OD at 280nm, 
lyophylized, and resuspended in 0.15 M 
NaC1, 20 mM HEPES, pH 7.8. A more 
detailed description of the synthesis and 
purification of conjugate, as well as the 
formation of complex, will be provided 
elsewhere. 
Oligonucleotides, Plasmids, and Cell 
Lines. ixm 18-base phosphorothioate oligonu- 
cleotide with the sequence: 5'-AGT- 
GATTTTTTTCTCCAT-3', which is comple- 
mentary to the translational initiation 
methionine of the CAT RNA, was synthe- 
sized. A control phosphorothioate oligonucle- 
otide, which is complementary to the transla- 
tional initiation methionine of the S-gene of 
hepatitis B virus, was also generated with the 
sequence: 5'-TGATGTGATGTTCTCCAT- 
3'. Both oligonucleotides were synthesized 
on an Applied Biosystems model 391B DNA 
synthesizer (DNA Synthesis Core). Full- 
length oligonucleotides were purified by 
UV-shadowing following electrophoresis on 
a 15% polyacrylamide-7 M urea gel. Purified 
oligonucleotides were resuspended in 10 mM 
Tris--HC1, 1 mM EDTA, pH 7.4. 3T3 fibro- 
blasts transduced with the cDNAs for the H1 
and H2b domains of the asialoglycoprotein 
receptor (171 cells) were graciously provided 
by Drs. Michael Shia and Harvey Lodish 
(27). An [125I]AsOR degradation assay was 
performed to document the persistent expres- 
sion of functional asialoglycoprotein recep- 
tor. The cells were maintained in culture in 
DMEM, 10% calf serum, 1% penicillin- 
streptomycin at 37°C in 5% CO2. The CAT 
clonal cell lines were produced by transfec- 
tion of 171 cells with the plasmid pRSV-CAT 
and pSV2his (10:1 ratio) and selected in 
DMEM, 10% heat-inactivated calf-serum, 
1% penicillin-streptomycin, and 0.12 mM 
histidinol (28). IndMdual clonal cell lines 
were screened for CAT enzymatic activity by 
enzyme assay and indirect immunofluores- 
cence. CAT-producing cell lines were then 
rescreened for retention of the asialooroso- 
mucoid receptor by molecular conjugate- 
mediated delivery of [3-actin nuclear-tar- 
geted lac Z ([3A-ntlacZ) plasmid DNA. 
Evidence for the receptor-mediated transfec- 
tion was provided by staining the cells for 
[3-galactosidase activity as previously de- 
scribed (29). 
Generation of Molecular Conjugate- 
Oligonucteotide Complexes. To determine the 
ratio of conjugate to oligonucleotide re- 
quired for the formation of a soluble com- 
plex, an agarose-gel retardation assay was 
performed. For this assay, 100 ng of the 
18-mer was end-labeled with [7-32p]ATP 
(3000 Ci/mmol, NEN-DuPont) using T4 
polynucleotide kinase (Boehringer-Mann- 
helm Biochemical). Labeled oligo (1.0 ng) 
was mixed with excess unlabeled oligonucleo- 
tide (99 ng) in order to perform the assay. 
The total amount of oligonucleotide re- 
mained constant in all samples. The oligonu- 
cleotide was mixed with increasing amounts 
of conjugate in the following ratios 0:1, 0.1:1, 
0.5:1, i:1, 2:1, 5:1, and t0:1. The DNA- 
conjugate suspension was incubated for 30 
min at room temperature. The reaction 
products were then analyzed on a 1.5% 
agarose gel. The gel was electrophoresed at 
50 V for 2 h, dried down, and exposed to film 
overnight (Kodak, X-OMAT XAR 5). 
Deliver), of Antisense Oligonucleotides 
into 171-CATCells. Confluent 171-CAT cells 
were split 1:10 the day prior to transfection. 
Four hours prior to the addition of complex, 
the growth media was changed to DMEM, 
10% heat-inactivated calf serum (68°C, 1 h), 
1% penicillin-streptomycin, and i mM CaC12 
Oligonucleotide-containing complexes were 
formed using the following protocol: The 
562 Bunnell et al.  
oligonucleotide-to-conjugate ratios were var- 
ied from 0:1 to 10:1 (mass ratio). The 
AsOR-poly(L-lysine) conjugate was diluted 
to an appropriate concentration in 0.1.5 M 
NaC1, 20 mM HEPES, pH 7.8, in a total 
volume of 500 lxl. The oligonucleotide was 
resuspended in 10 mM Tris-HC1, 1 mM 
EDTA, pH 7.4. A predetermined amount of 
oligonucleotide was then transferred to a 
solution of 0.15 M NaC1, 20 mM HEPES, pH 
7.8 in a final volume of 500 /,I. The 
oligonucleotide and conjugate preparations 
were then mixed together for a final volume 
of 1 ml, gently vortexed, incubated at room 
temperature for 30 min, and filtered through 
a 0.45 txm filter prior to its addition to the 171 
cells. The complex (1 ml) was added directly 
to 4 ml of the DMEM, 10% heat-inactivated 
calf serum, 1% penicillin-streptomycin, and 
1 mM CaC12 in the presence of 50 ~M 
chloroquine (Sigma). Cells were incubated in 
the presence of complex for 24 h and then 
analyzed for CAT activity by indirect immu- 
nofluorescence and enzyme assay of lysates. 
Functionality of Oligonucleotide Molec- 
ular Conjugates. In an attempt to examine 
the effectiveness of the oligonucleotide to- 
roids, the incorporation of labeled oligonucle- 
otide into tissue culture cells was assessed in 
the context of free oligonucleotide versus 
complexed oligonucleotide. For this analysis, 
500 ng of the 18-mer oligonucleotide was 
end-labeled with [~-3~P]ATP (3000 Ci/mol, 
NEN-DuPont) using T4 polynucleotide ki- 
nase (Boehringer Mannheim Biochemical). 
A total of 1 x 106 cpm of purified oligonucle- 
otide (100 ng) was mixed with excess unla- 
beled oligonucleotide (100 ~g) to efficiently 
form toroids when the DNA was mixed with 
conjugate at a 5:1 ratio. An equivalent 
amount of free oligonucleotide was prepared 
but not complexed to conjugate. Both 171 
and 3T3 cells were split to a density of 5 x 
105 cells in a 60-mm tissue culture dish in 
DMEM, 10% heat-inactivated calf serum, 
1% penicillin-streptomycin, and i mM CaC12. 
Four hours prior to the addition of oligonu- 
cleotide, the media on the cells was replaced 
with fresh media. The cells were then 
incubated with the free and complexed 
oligonucleotide samples over a 3-h time 
period with samples removed at predeter- 
mined intervals of 0, 15, 30, 60, 120, and 180 
min. For each time point, the cells were 
trypsinized off the dish, washed twice in PBS, 
and then incubated with DNase (1 unit/~g) 
for 1 h at 37°C. The samples were then 
pelleted in a microfuge at 4°C for 5 min, 
washed three times in PBS, and finally 
analyzed by scintillation counting. 
Chloramphenicol Acetyltransferase As- 
says. The net inhibition of CAT activity in 
the cell population was estimated by perform- 
ing enzyme assays of cell lysates. The cells 
were washed twice in PBS, and scraped from 
the plate in 1 ml of TNE (0.04 M Tris HCI, 
pH 7.4, 1 mM EDTA, 0.15 M NaCI) and 
placed in microfuge tubes and stored on ice. 
The cells were pelleted in a microfuge for 3 
min at 4°C, the supernatant aspirated, and 
the cell pellet frozen at -20°C. The cell 
pellets were resuspended in 100 ixI of 0.25 M 
Tris HCI, pH 7.8. The cells were frozen in a 
dry ice-ethanol bath for 5 min and immedi- 
ately placed at 37°C for 5 rain. The freeze- 
thawing was repeated two additional times to 
generate the cell lysate. Protein concentra- 
tion was assayed by performing a Bradford 
protein assay. Cell extract (20 Ixg) was 
assayed for CAT activity in the presence of 
50 ~Ci [14C]chloramphenicol (Amersham), 
0.25 M Tris HC1, pH 7.8, 0.5 mM acetyl-CoA 
(Pharmacia) at 37°C for 30 rain. Reactions 
products were extracted in 1 ml ethyl acetate, 
dried down in a speed-vac, resuspended in 30 
txl ethyl acetate, and spotted onto thin-layer 
chromatography plates (Kodak, Chro- 
magram). Chromatography was performed 
in chloroform-methanol (19:1, v/v). CAT 
assays were analyzed and quantified on a 
Betagen scanner. 
Indirect Irnmunofluorescent Detection of 
CAT. The efficiency of delivery of antisense 
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oligonucleotides by the complexes was stud- 
ied at the cellular level using a rabbit 
polyclonal antibody generated against CAT 
(5'-3'). The transfected cells were grown and 
transfected on glass cover slips for this 
analysis. After 24 h in the presence of 
complex, the cells were washed twice in 
phosphate-buffered saline (PBS) and fixed in 
methanol for 10 min on ice. Cover slips were 
subsequently washed in PBS and incubated 
in a 1:100 dilution of CAT antibody for 30 
min at 37°C. The primary antibody was 
detected by incubating cells in FITC- 
conjugated goat anti-rabbit IgG (1:200) for 
30 min at 37°C. After washing in PBS, the 
cover slips were mounted in Citifluor mount- 
ing media (Citifluor LTD) and examined 
using a Microphot-FXA microscope (Ni- 
kon). 
Electron Microscopy. Solutions of com- 
plex were incubated on collodion-carbon- 
coated grids at room temperature. Excess 
solution was removed by capillary action and 
the samples were negatively stained by 
incubation in 2% uranyl magnesium acetate. 
At least two grids were examined for each 
complex sample using a Phillips CM-10 
transmission electron microscope. All struc- 
turally defined complex macromolecules were 
documented by photomicrographs. 
RESULTS 
Binding of oligonucleotide to conjugate 
was assessed by a simple electrophoretic 
assay in which the products of the DNA-  
protein complex formation were electropho- 
resed through a nondenaturing agarose gel. 
Increasing amounts of conjugate (0-1 tzg) 
were added to a mixture of tracer 32p_ 
end-labeled oligonucleotide (1 ng) and unla- 
beled oligonucleotide (99 ng). Autoradiogra- 
phy of a typical experiment is presented in 
Fig. i. Free oligonucleotide migrates far into 
the gel while complexed otigonucleotide is 
markedly retarded. Increasing the conjugate- 
to-oligonucleotide ratio to 5:1 leads to 
Fig. 1. Gel retardation assay of free and comptexed 32p 
end-labeled oligonucleotide. The 18-base CAT anti- 
sense oligonucleotide was end-labeled with [y-32p]ATP 
using T4 polynucleotide kinase. A tracer amount of 
labeled oligonucleotide (1 ng) and excess unlabeled 
oligonucleotide (99 ng) were mixed in a 25 I~ of 0.15 M 
NaCI, 20 mM HEPES, pH 7.8, and incubated with 0, 10, 
25, 50, 100, 200, 500, and 1000 ng of AsOR-poly(L- 
lysine) conjugate also in 25 g (of 0.15 M NaCI, 20 mM 
HEPES, pH 7.8, incubated for 30 rain at room 
temperature, and then electrophoresed through a 1.5% 
agarose gel. The get was dried and exposed to film 
overnight. The amount of conjugate and oligonucleotide 
in each sample is indicated above and the state of the 
oligonucleotide is indicated by the arrows (complexed 
oligonucleotide vs. free oligonucleotide). 
complete formation of complex that does not 
electrophorese out of the well. 
In an attempt to define the structure of 
the resulting DNA-protein complex, the 
products of reactions analyzed in Fig. 1 were 
further characterized by electron microscopy 
using negative staining. Complex formed at 
mass ratios of conjugate-DNA less than or 
equal to 2:1 revealed no specific macromolec- 
ular structures. As shown in Fig. 2, when the 
mass ratio of conjugate to oligonucleotide 
was increased to 5:1, donutlike structures 
with diameters ranging from 50 to 150 nm 
were consistently observed. Similar struc- 
tures, called toroids, have been previously 
observed as a result of binding polycations to 
high-molecular-weight DNA (30). 
Functionality of the AsOR-poly(L- 
lysine)-oligonucleotide complexes was as- 
sessed using a mouse fibroblast cell line 
genetically modified to stably express the 
asialoglycoprotein (ASGP) receptor and 
CAT. The cell line used in the present study 
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Fig. 2. Etectron microscopic analysis of oligonucleotide- 
conjugate macromolecular structure. The same samples 
used for gel retardation assay were analyzed by electron 
microscopy. (A) A 40,000x magnification of negatively 
stained toroids observed by formation of complex with 
100 ng oligonucleotide and 500 ng conjugate, size bar 
represents 1 Ixm. (B) A 219,000× magnification of 
negatively stained oligonucleotide derived toroids, size 
bar represents 100 nm. 
is called 171. Since the 171 cells were directly 
derived from NIH 3T3 ceils, this provided 
the unique opportunity to retain a genetic 
control in terms of ASGP receptor expres- 
sion. The role of the ASGP receptor in the 
mediation of uptake of molecular conjugates 
can be assessed by direct comparison of 171 
and 3T3 cells that have been engineered to 
express CAT. 
The effectiveness of molecular conju- 
gates for delivery of oIigonucleotides into 
eukaryotic cells was assessed by monitoring 
uptake of free and complexed 32p end- 
labeled oligonucleotide. Figure 3 demon- 
strates the results of incorporation of free 
and complexed oligonucleotide into 171 and 
3T3 cells. In the presence of free oligonucle- 
otide, both cell lines showed a time- 
dependent increase in the label associated 
with the cells pellet over the time period. 
However, when the cells are incubated in 
presence of oligonucleotide toroids, a time- 
dependent incorporation of oligonucleotide 
was only obsel-v-ed in the 171 cells. Addition- 
ally, the amount of label associated with the 
cell pellet was threefold greater in the 171 
cells when it was in the context of a toroid as 
opposed to free oligonucleotide. 
The 171 cell line was exposed to 
increasing concentrations of oligonucleotide 
complexes (DNA ranging from 0 to 100 txg in 
complexes formed at a conjugate to oligonu- 
cleotide ratio of 5:1) for 24 h in the presence 
of chloroquine. The cells were analyzed for 
changes in expression of CAT by simulta- 
neous assays for enzymatic activity in cell 
lysates and indirect immunofluorescence to 
detect protein at a cellular level. Figure 4A 
summarizes the effect of increasing concen- 
trations of oligonucleotide complex on CAT 
activity in whole cell lysate. Increasing the 
10"3cpm 
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Fig. 3. Comparison of uptake of 32p-end- 
labeled oligonucleotide into 171 and 3T3 
cells. One x 106 cpm of endqabeled oligo- 
nucleotide (100 ng) was incubated on 5 x 
105 cells in both free and complexed forms 
for variable lengths of time from 0 min up to 
360 rain. The average amount of uptake from 
three experiments is represented graphi- 
cally as follows: open circles, 3T3 cells + 
complexed oligonucleotide; open squares, 
3T3 cells + free otigonucleotide; closed 
squares, i71 cells + free oligonucleotide; 
and dosed circles, 171 cells + complexed 
oligonucleotide. 
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Fig. 4. Analysis of CAT gene expression in 171 cells 
transfected with oligonucleotide-AsOR-poly(L-lysine) 
complexes. Complexes containing increasing amounts of 
CAT antisense oligonucleotide were lormed and incu- 
bated on the cells for a 24-h period. Control experiments 
of competition of uptake by incubation of complex in the 
presence of a molar excess of free AsOR (1 mg) and 
formation of complex with an irrelevant HBV oligonucle- 
otide were also performed. The genetic negative control 
3T3 cells expressing CAT also demonstrated no inhibi- 8 
tion of CAT activity when incubated in the presence of 
oligonucleotide toroids. After the incubation, the cells 
were harvested and analyzed using both an enzyme assay 
and indirect immunofluorescence. Cell lysates were 
prepared by freeze-thawing. (A) Results of CAT _ 
enzyme assays on 20 ~xg of cell lysate depicted as percent ~- 
inhibition of CAT activity. (B) Results of analysis for 
CAT protein by indirect immunofluorescence with a 
rabbit polyclonal antibody to the CAT protein. More 
o than 500 cells were analyzed for each duplicate sample ,~ 
and only those scoring completely negative for immuno- 
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concent ra t ion  of  C A T  antisense ol igonucleo- 
tide toroids in the media  was associated with 
inhibition of  C A T  activity in the lysate to a 
maximum of  54 _+ 4% (mean  +_ 1 SD, N >_ 3) 
inhibition. This inhibition was prevented  
when the toroids were  incubated  with an 
excess of  the  A s O R ,  indicating that  it is the 
result of  recep tor -media ted  up take  pro- 
cesses. Inhibi t ion of  C A T  activity was not  
observed with toroids containing oligonucle- 
otides against the S-gene region of  hepatit is  
B virus, indicating that  the effect is sequence-  
specific and not  a nonspecific effect o f  toroid  
uptake.  Incubat ion  of  3 T 3 - C A T  cells with 
ol igonucleot ide toroids revealed no inhibi- 
t ion of  C A T  activity in cell extracts. 
Dupl ica te  plates were also analyzed for 
antisense funct ion by est imating the cell- 
specific expression of  C A T  prote in  using 
immunohis tochemistry .  Exposure  of  the cells 
to increasing concent ra t ions  of  C A T  oligonu- 
cleotide toroids led to the appearance  o f  a 
subpopula t ion  of  cells completely  void o f  
C A T  protein.  A maximum of  33 + 4% 
(mean _+ 1 SD, N >_ 3) nonexpressing cells 
was achieved with 100 ~g of  ol igonucleot ide 
in toroids. A n  example of  this analysis is 
shown in Fig. 5. 171 cells t ransfected with 
conjugate  alone showed bright f luorescence 
in > 95% of  the cells (panels A and B), while 
t ransfect ion with C A T  ot igonucleot ide to- 
roids was associated with a substantial 
reduct ion of  f luorescence in a subpopula t ion  
of  the cells (panels C and D). No  alterations 
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Fig. 5. An example of CAT immunohistochemistry in 171 cells. Cells were fixed for 10 rain in methanol and washed 
with phosphate-buffered saline (PBS). CAT protein was detected as described in Materials and Methods. (A) 
Control cells transfected with 500 pxg of AsOR-poly(L-lysine) conjugate alone viewed under Nomarski optics. (B) 
Immunofluorescent detection of CAT in conjugate-transfected cells. (C) Nomarski optic view of cells transfected 
with oligonucleotide containing complexes (100 ~xg oligonucleotide and 500 ~g conjugate). (D) Immunofluorescent 
detection of CAT protein in oligonucleotide complex transfected cells. Cells lacking staining are indicated by arrows. 
Size bar represents 160 ixm. 
in the immunofluorescent  staining pat tern 
was observed in the 3T3 CAT cell line. The 
specificity of antisense inhibition was again 
confirmed by the absence of an effect with 
toroids coincubated with excess AsOR or 
toroids containing HBV antisense oligonucle- 
otides. 
Having demonstra ted the function of 
antisense-containing toroids, conditions were 
determined to optimize their activity in vitro. 
Complexes formed with different ratios of 
conjugate and D N A  were characterized with 
respect to inhibition of CAT activity in 171 
cells (Fig. 6). Complexes formed with protein- 
to -DNA mass ratios of up to 2:1 showed 
insignificant levels of inhibition of CAT 
expression, while complexes formed at the 
5:1 and 10:1 mass ratios showed a marked 
increase in the levels of inhibition of CAT 
activity. 
In order to more fully understand the 
effectiveness of the oligonucleotide com- 
plexes as a delivery system, 171 CAT cells 
were incubated in the presence of increasing 
concentrations of naked oligonucleotides up 
to a maximum of 30 p.M (850 Ixg/5 ml). As 
shown in Fig. 7, the level of inhibition of 
CAT expression is proportional  to the 
concentration of oligonucleotide with 62 _+ 
4% (mean  _+ 1 SD, N >_ 3) inhibi t ion 
achieved with free oligonucleotide. Analysis 
of these cells by indirect immunofluores- 
cence for the CAT protein revealed a broad 
range of residual CAT protein, but showed 
only a few cells in which CAT expression was 
totally inhibited ( ~ 5%, data not shown). 
D I S C U S S I O N  
A significant problem with in vivo 
applications of antisense oligonucleotide 
technology is the difficulty associated with 




Fig. 6. CAT enzyme analysis of cells transfected ,,. '~ so 
with oligonucleotide complexes formed with vary- o ~= 
ing conjugate concentrations. A constant 100 Ixg of ~ ¢ 
oligonucleotide was incubated with varying amounts N E 40 
of conjugate (0, 10, 50, 100, 200, 500, and 1000 lag) 'g 
in a 1-ml final volume, as previously described. 171 .~uae ~" 
cells were transfected for 24 h and celt lysates ~ 30 
prepared by freeze-thaw fracture; 20 p.g of cell 
tysate was used per assay. Data are represented as 
percent inhibition of CAT activity. 20 
10 
0 0.1:1 0.5:1 t ;1 2:1 5:1 
Conjugate : Oligonucleotide Ratio 
10:1 
de l ive r ing  large a m o u n t s  of  o l i g o n u c l e o t i d e  
to a specif ic  p o p u l a t i o n  of  cells.  I n  sea rch  o f  
a n  ef f ic ient  a p p r o a c h  for o l i g o n u c l e o t i d e  
del ivery,  m o l e c u l a r  c o n j u g a t e s  we re  inves t i -  
g a t e d  for  t he i r  abi l i ty  to f u n c t i o n  in  this  
capaci ty .  T h e  d a t a  p r e s e n t e d  h e r e  i nd i ca t e  
80 ~ 
Fig. 7. CAT enzyme activity analysis of cells 
incubated in the presence of uncomplexed oligonu- 
cleotide. 17t cells were incubated with varying 
amounts of oligonucleotide 0, 250, 425, 850 Ixg in 
DMEM, 10% heat inactivated calf serum, 1% 
penicillin-streptomycin, 1 mM CaCla for 24 h. 
Cells were harvested and lysed as previously 
described; 20 lag of cell lysate was used per assay. 







tha t  m o l e c u l a r  c o n j u g a t e s  c an  effect ively be  
u t i l i zed  as an  a l t e r n a t i v e  a p p r o a c h  to de l ive r  
o l i g o n u c l e o t i d e s  in to  cells.  
Severa l  a p p r o a c h e s  have  b e e n  deve i -  
o p e d  for  de l ivery  of  o l i g o n u c l e o t i d e s  in  vi tro.  
T h e  s t a n d a r d  a p p r o a c h  involves  i n c u b a t i n g  
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the naked oligonucleotides in the culture 
media. The oligonucleotide is transported 
into the cell by active transport mechanisms. 
The drawback of this approach is that 
milligram quantities of oligonucleotide are 
often required to observe inhibitory effects. 
Direct microinjection of oligonucleotides 
into cells has been successfully utilized to 
deliver large quantities of oligonucleotide to 
cells (31). However, this approach is severely 
limited by the inability to inject oligonucleo- 
tide into a large number of cells. Lastly, 
liposome-mediated delivery of oligonucteo- 
tides has been used as a moderately success- 
ful nonspecific approach for delivery (32). 
The method described in this report is 
based on the stable and nondestructive 
interactions of phosphorothioate oligonucte- 
otides and the AsOR-poly(L-lysine) conju- 
gates. Under appropriate conditions mix- 
tures of oligonucleotide and conjugate form 
a stable toroidal structure easily visualized 
under EM. This structure resembles a donut 
of 50-150 nm in diameter. Our studies 
indicate that the toroidal structure is neces- 
sary to achieve efficient antisense delivery. 
The toroids formed with the oligonucleotide 
have the same range of diameter as those 
formed with plasmid DNA, indicating that 
there may be a standard size range for the 
toroids, which would provide a great deal of 
continuity for the use of molecular conju- 
gates for gene delivery (data not shown). 
An important factor in the use of 
molecular conjugates for the delivery of 
antisense oligonucleotides is the ability to 
significantly reduce gene expression with 
substantially less oligonucleotide. The deliv- 
ery of oligonucleotides in the context of a 
toroid appears to be much more efficient 
than uptake by the active transport mecha- 
nism of free oligonucleotides, as demon- 
strated by the incorporation of 32P-labeled 
oligonucleotide in the context of a toroid. 
Fivefold less oligonucleotide was required to 
achieve 50% inhibition of CAT when it is 
delivered in the context of a toroid. It is also 
important to note that when oligonucleotides 
were delivered by molecular conjugates, 
there was a significant subpopulation of cells 
that lacked any detectable CAT activity. 
Cells incubated with noncomplexed oligonu- 
cleotide showed a reduction in CAT activity, 
but when examined by indirect immunofluo- 
rescence > 95% of the cells retained some 
levels of CAT protein. The improved delivery 
of oligonucleotides by molecular conjugates 
marks a significant improvement in the 
effectiveness of antisense oligonucleotides 
for the inhibition of gene expression. 
Another significant advantage of molec- 
ular complexes is the potential for the 
cell-specific targeting of oligonucleotide deliv- 
ery. The uptake of the AsOR-poly(L-lysine)- 
oligonucleotide complexes is clearly medi- 
ated by the ASGP receptor found on the 171 
cells. The fact that a preselected receptor 
ligand is utilized in the formation of the 
complexes should permit them to be targeted 
to a specific population or subset of cells 
within a heterogenous population. Providing 
that the complexes are stable in vivo, this 
specificity should provide a viable approach 
to efficiently deliver large amounts of the 
oligonucleotide precisely to a selected target 
organ. 
In this report, we summarize the devel- 
opment of a system for the efficient and 
targeted delivery of antisense oligonucleo- 
tides to eukaryotic cells. The use of molecu- 
lar conjugates for the delivery of oligonucleo- 
tides may prove to be a significant 
advancement in the area of antisense oligonu- 
cleotide derived therapies. Experiments are 
currently in progress to examine the effective- 
ness of molecular conjugates in vivo. 
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